FDA Issues Warning to Supplement Retailer
Retailers of natural products face heightened scrutiny over marketing claims that imply medical treatment of diseases.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Should herbal supplements marketed for treating diseases be regulated as strictly as pharmaceutical drugs?
The Food and Drug Administration issued a warning letter to Best Chinese Medicines LLC for marketing five herbal products with unapproved medical claims. Sellers of natural health supplements must ensure product descriptions align with federal requirements for labeling and disease prevention claims.
Why it matters
The FDA identified these products as unapproved new drugs due to claims they treat conditions like hypertension and Covid-19, which triggers strict regulatory compliance requirements. Operating in the supplement space requires clear distinction between dietary support and disease treatment to avoid legal enforcement.
The FDA flagged five products for unauthorized disease treatment claims, including Dissolve Mass Stasis Breaker and Lianhua Qingwen Capsules. The company has 15 business days to respond to the issues raised in warning letter number 738556.
The players
Food and Drug Administration
The federal agency responsible for protecting public health by regulating the safety and labeling of drugs, food, and medical devices.
Best Chinese Medicines LLC
A distributor of herbal supplements based in Lake Kiowa, TX, currently under regulatory scrutiny for its marketing claims.
The details
The FDA determined the products function as drugs under federal law because they are marketed to diagnose, cure, mitigate, or treat diseases like osteoarthritis and arrhythmias. By auditing the website bestchinesemedicines.com, regulators found the company lacked approved applications for these specific medical claims. Failure to address these violations in the company's response can lead to escalated enforcement actions, including product seizures or legal injunctions.
Timeline
September 2026: The FDA conducted an initial website review.
October 23, 2026: The FDA issued the official warning letter.
Within 15 business days of receipt: The company must provide a written response.
Market Landscape
This enforcement action aligns with the FDA's broader oversight of dietary supplement companies claiming to treat specific illnesses. It highlights the recurring regulatory tension between herbal retailers and the Federal Food, Drug, and Cosmetic Act requirements for evidence-based medicine.
Operators in the supplement sector should audit website claims to ensure they do not market products as diagnostic or curative tools. Consult legal counsel to confirm labeling compliance and avoid the operational risks associated with FDA warning letters and potential product seizures.
The takeaway
Retailers must ensure marketing materials do not cross the line from general wellness support into prohibited medical claims for specific diseases. Verify all current product labeling against federal guidelines and prioritize a prompt, documented response to agency inquiries to minimize enforcement risk.
Further reading
For more on regulatory standards, visit our section on Healthcare.
More information
Review the official FDA warning letter for complete compliance details.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Should herbal supplements marketed for treating diseases be regulated as strictly as pharmaceutical drugs?
